Zealand Pharma A/S (OTCMKTS:ZLDPF) Stock Price Up 1.3%

Zealand Pharma A/S (OTCMKTS:ZLDPF)’s stock price shot up 1.3% on Wednesday . The company traded as high as $88.12 and last traded at $87.23. 327 shares traded hands during trading, a decline of 88% from the average session volume of 2,689 shares. The stock had previously closed at $86.08.

Analyst Ratings Changes

Separately, BTIG Research started coverage on shares of Zealand Pharma A/S in a research note on Thursday, March 7th. They set a “buy” rating for the company.

Zealand Pharma A/S Trading Up 0.7 %

The firm’s 50-day simple moving average is $92.63 and its two-hundred day simple moving average is $67.03. The stock has a market capitalization of $4.47 billion, a PE ratio of -47.68 and a beta of 0.63.

Zealand Pharma A/S (OTCMKTS:ZLDPF) last issued its earnings results on Tuesday, February 27th. The company reported ($0.66) EPS for the quarter, missing analysts’ consensus estimates of ($0.58) by ($0.08). The firm had revenue of $3.35 million during the quarter, compared to analysts’ expectations of $1.97 million. Zealand Pharma A/S had a negative net margin of 203.99% and a negative return on equity of 49.78%. As a group, research analysts expect that Zealand Pharma A/S will post -2.56 earnings per share for the current year.

Zealand Pharma A/S Company Profile

Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. The company offers Dasiglucagon, a single use syringe or autoinjector for the treatment of severe hypoglycemia; and Dasiglucagon bi-hormone artificial pancreas systems containing insulin and dasiglucagon.